Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium

[1]  W. Choi,et al.  Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP , 2015, Modern Pathology.

[2]  W. Choi,et al.  Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions , 2015, Modern Pathology.

[3]  Roland Schmitz,et al.  Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma , 2015, Nature Medicine.

[4]  W. Choi,et al.  Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma , 2015, Oncotarget.

[5]  K. Young,et al.  Genetic lesions in diffuse large B-cell lymphomas. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Su-Jin Shin,et al.  TCL1 expression predicts overall survival in patients with mantle cell lymphoma , 2015, European journal of haematology.

[7]  M. Mokry,et al.  FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cells. , 2014, Blood.

[8]  P. Went,et al.  Phenotype profiling of primary testicular diffuse large B‐cell lymphomas , 2014, Hematological oncology.

[9]  J. Cerhan,et al.  Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Jing Zhang,et al.  Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis , 2014, Leukemia & lymphoma.

[11]  W. Choi,et al.  Prevalence and Clinical Implications of Epstein–Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries , 2014, Clinical Cancer Research.

[12]  C. Cheah,et al.  Primary testicular lymphoma. , 2014, Blood.

[13]  W. Choi,et al.  MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. , 2013, Blood.

[14]  Wen-Qi Jiang,et al.  Three prognostic factors influence clinical outcomes of primary testicular lymphoma , 2013, Tumor Biology.

[15]  W. Choi,et al.  Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. , 2012, Blood.

[16]  Michael W. McCormick,et al.  Shaping of Human Germline IgH Repertoires Revealed by Deep Sequencing , 2012, The Journal of Immunology.

[17]  K. Dybkær,et al.  Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study , 2012, Leukemia.

[18]  Michael A. Freitas,et al.  Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL) , 2012, Proceedings of the National Academy of Sciences.

[19]  L. Kwak,et al.  TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. , 2011, Blood.

[20]  R. Gascoyne,et al.  Diffuse Large B-Cell Lymphoma with Testicular Involvement: Outcome and Risk of CNS Relapse in the Rituximab Era , 2011 .

[21]  A. López-Guillermo,et al.  First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Xiaoyan Zhou,et al.  FOXP1 expression and its clinicopathologic significance in nodal and extranodal diffuse large B-cell lymphoma , 2011, Annals of Hematology.

[23]  K. Karube,et al.  Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma. , 2011, Blood.

[24]  G. Barber,et al.  T-cell leukemia 1 expression in nodal Epstein-Barr virus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. , 2010, Human pathology.

[25]  P. Iyengar,et al.  Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience , 2010, Leukemia & lymphoma.

[26]  P. Went,et al.  Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores , 2010, Leukemia & lymphoma.

[27]  M. Hallek,et al.  High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. , 2009, Blood.

[28]  Michelle A. Mathiason,et al.  Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  A. Avilés,et al.  Rituximab and dose-dense chemotherapy in primary testicular lymphoma. , 2009, Clinical lymphoma & myeloma.

[30]  L. Staudt,et al.  Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.

[31]  R. Go,et al.  Adult testicular lymphoma in the United States (1985–2004): Analysis of 3,669 cases from the National Cancer Data Base (NCDB) , 2008 .

[32]  P. Park,et al.  Pathway analysis of primary central nervous system lymphoma. , 2008, Blood.

[33]  Markus Loeffler,et al.  Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.

[34]  N. Shinton.  WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[35]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  T. Ulbright,et al.  Primary testicular diffuse large B-cell lymphoma belongs to the nongerminal center B-cell-like subgroup: a study of 18 cases , 2006, Modern Pathology.

[37]  A. Glas,et al.  Primary testicular diffuse large B‐cell lymphomas have activated B‐cell‐like subtype characteristics , 2006, The Journal of pathology.

[38]  Randy D Gascoyne,et al.  Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  P. de Paepe,et al.  Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  A. Rosenwald,et al.  Mechanisms and Effects of Loss of Human Leukocyte Antigen Class II Expression in Immune-Privileged Site-Associated B-Cell Lymphoma , 2006, Clinical Cancer Research.

[41]  A. López-Guillermo,et al.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.

[42]  J. Fridlyand,et al.  Gene expression and angiotropism in primary CNS lymphoma. , 2006, Blood.

[43]  P. Marynen,et al.  FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations , 2005, Leukemia.

[44]  P. Gaulard,et al.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  A. Avilés,et al.  Testicular Lymphoma: Organ-Specific Treatment Did Not Improve Outcome , 2004, Oncology.

[46]  S. Barrans,et al.  Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. , 2004, Blood.

[47]  R. Gascoyne,et al.  Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  E. Jordanova,et al.  β2‐microglobulin aberrations in diffuse large B‐cell lymphoma of the testis and the central nervous system , 2003 .

[49]  P. Colombat,et al.  Stage I-IIE primary non-Hodgkin's lymphoma of the testis: results of a prospective trial by the GOELAMS Study Group. , 2002, Clinical lymphoma.

[50]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[51]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[52]  H. Prince,et al.  Primary large-cell non-Hodgkin's lymphoma of the testis: a retrospective analysis of patterns of failure and prognostic factors. , 2001, Clinical lymphoma.

[53]  F. Cabanillas,et al.  Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy? , 2001, Clinical lymphoma.

[54]  E. Jordanova,et al.  Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. , 2000, Blood.

[55]  J. Laine,et al.  The protooncogene TCL1 is an Akt kinase coactivator. , 2000, Molecular cell.

[56]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[57]  D. Ellison,et al.  V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity. , 1999, Blood.

[58]  C Tondini,et al.  Diffuse large-cell lymphoma of the testis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  J. Cox,et al.  Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  M. Isobe,et al.  Identification of the TCL1 gene involved in T-cell malignancies. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[62]  A. Crellin,et al.  Non-Hodgkin's lymphoma of the testis. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[63]  J. Connors,et al.  Testicular lymphoma: improved outcome with early brief chemotherapy. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  J. Earle,et al.  Primary Lymphoma of the Testis , 1983 .

[65]  K. Young,et al.  Diffuse large B-cell lymphoma. , 2018, Pathology.

[66]  E. Devilard,et al.  Identification of TCL1A as an immunohistochemical marker of adverse outcome in diffuse large B-cell lymphomas. , 2005, International journal of oncology.

[67]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[68]  F. Cavalli,et al.  Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.